Photogen restructures to focus on core products:
This article was originally published in Clinica
Executive Summary
New Hope, Pennsylvania-based Photogen Technologies will use the $16.25m raised from financing agreements to implement its restructuring plan, allowing it to concentrate resources on its cardiovascular imaging and lymphography products, PH-50 and N-1177, respectively. The company is splitting off its photodynamic therapy and laser device business to five founding shareholders, in exchange for all their common stock, some 52.9% of the company's shares.